Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes

Robert W Kirchoff, Norhan M Mohammed, Jack McHugh, Matej Markota, Thomas Kingsley, Jonathan Leung, M Caroline Burton, Rahul Chaudhary, Robert W Kirchoff, Norhan M Mohammed, Jack McHugh, Matej Markota, Thomas Kingsley, Jonathan Leung, M Caroline Burton, Rahul Chaudhary

Abstract

Alcohol use disorder (AUD) is a highly prevalent health issue in the United States. The number of those receiving medication-assisted treatment (MAT) is limited, despite strong evidence for their effectiveness. The inpatient setting may represent an important opportunity to initiate MAT. The goal of this study was to summarize the data on naltrexone initiation in the emergency department or inpatient setting for the management of AUDs. We searched ClinicalTrials.gov, Ovid EBM Reviews, Ovid Embase, Ovid Medline, Ovid PsycINFO, Scopus, and Web of Science from inception through October 31, 2019. Search strategies were created using a combination of keywords (Supplemental Appendix 1, available online at http://www.mcpiqojournal.org) and standardized index terms related to naltrexone therapy for medically hospitalized patients with AUD. Two uncontrolled pre-post study designs evaluated naltrexone prescription rates, 30-day readmission rates, and rehospitalization rates. Two authors independently abstracted data on study characteristics, results, and study-level risk of bias. The research team collaborated to assess the strength of evidence across studies. Two studies reported that implementing a protocol for naltrexone initiation increased MAT rates, with one study noting a substantial decrease in 30-day hospital readmissions. Overall, we found that there is a paucity of data on naltrexone initiation in the inpatient setting for AUDs. This likely reflects the nature of current clinical practice and prescriber comfortability. There is a need for further studies evaluating MAT initiation in the inpatient setting. Furthermore, efforts to increase provider knowledge of these therapeutic options are in need of further exploration.

Keywords: AUD, alcohol use disorder; FDA, US Food and Drug Administration; MAT, medication-assisted treatment; RCT, randomized controlled trial.

© 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.

Figures

Figure
Figure
PRISMA 2009 flow diagram.

References

    1. Spillane S., Shiels M.S., Best A.F., et al. Trends in alcohol-induced deaths in the United States, 2000-2016. JAMA Netw Open. 2020;3(2):e1921451.
    1. Substance Abuse and Mental Health Services Administration . Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; Rockville, MD: 2019. Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health.
    1. Hasin D.S., Stinson F.S., Ogburn E., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–842.
    1. Yedlapati S.H., Stewart S.H. Predictors of alcohol withdrawal readmissions. Alcohol Alcohol. 2018;53(4):448–452.
    1. Volpicelli J.R., Alterman A.I., Hayashida M., O’Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–880.
    1. Lyon J. More treatments on deck for alcohol use disorder. JAMA. 2017;317(22):2267–2269.
    1. Swift R.M., Aston E.R. Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry. 2015;23(2):122–133.
    1. Jonas D.E., Amick H.R., Feltner C., et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900.
    1. Rösner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.
    1. Kurtzweil P. Medications can aid recovery from alcoholism. FDA Consumer Magazine. 1996
    1. Reus V.I., Fochtmann L.J., Bukstein O., et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86–90.
    1. Spanagel R., Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18(2):54–59.
    1. Srisurapanont M., Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;1:CD001867.
    1. Sterne J.A., Hernán M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
    1. Wei J., Defries T., Lozada M., Young N., Huen W., Tulsky J. An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits. J Gen Intern Med. 2015;30(3):365–370.
    1. Stephens J.R., Moore C., Stepanek K.V., et al. Implementation of a process for initiating naltrexone in patients hospitalized for alcohol detoxification or withdrawal. J Hosp Med. 2018;13(4):221–228.
    1. Harris A.H.S., Kivlahan D.R., Bowe T., Humphreys K.N. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatric Serv. 2010;61(4):392–398.
    1. Moos R.H., Mertens J.R., Brennan P.L. Rates and predictors of four-year readmission among late-middle-aged and older substance abuse patients. J Stud Alcohol. 1994;55(5):561–570.
    1. Louro Puerta R., Otero Antón E., Lorenzo Zúñiga V. Epidemiology of alcohol withdrawal syndrome: mortality and factors of poor prognosis [in Spanish] An Med Interna. 2006;23(7):307–309.
    1. Lawson P.J., Flocke S.A. Teachable moments for health behavior change: a concept analysis. Patient Educ Couns. 2009;76(1):25–30.
    1. Antonelli M., Ferrulli A., Sestito L., et al. Alcohol addiction—the safety of available approved treatment options. Expert Opin Drug Saf. 2018;17(2):169–177.
    1. Dawson D.A., Grant B.F., Stinson F.S., Chou P.S., Huang B., Ruan W.J. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction. 2005;100(3):281–292.
    1. Reif S., Acevedo A., Garnick D.W., Fullerton C.A. Reducing behavioral health inpatient readmissions for people with substance use disorders: do follow-up services matter? Psychiatr Serv. 2017;68(8):810-818.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel